Shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) fell 3% during trading on Thursday . The company traded as low as $10.14 and last traded at $10.32, with a volume of 164,021 shares. The stock had previously closed at $10.64.

A number of research firms recently commented on AIMT. Piper Jaffray Cos. reissued an “overweight” rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a report on Wednesday, June 29th. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a report on Monday, June 13th. Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, May 20th. Finally, Bank of America Corp. reaffirmed a “buy” rating on shares of Aimmune Therapeutics in a report on Monday, May 16th. Five equities research analysts have rated the stock with a buy rating, Aimmune Therapeutics has an average rating of “Buy” and an average target price of $33.40.

The stock’s market cap is $433.45 million. The stock’s 50-day moving average is $13.17 and its 200 day moving average is $14.72.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Monday, May 16th. The company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.03. On average, analysts forecast that Aimmune Therapeutics Inc. will post ($1.70) EPS for the current fiscal year.

In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total value of $3,655,200.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

A number of institutional investors recently added to or reduced their stakes in the stock. Eagle Asset Management Inc. bought a new position in Aimmune Therapeutics during the fourth quarter valued at approximately $15,794,000. Alps Advisors Inc. bought a new position in Aimmune Therapeutics during the fourth quarter valued at approximately $1,027,000. TLP Group LLC bought a new position in Aimmune Therapeutics during the fourth quarter valued at approximately $51,314,000. Finally, Aisling Capital LLC boosted its position in Aimmune Therapeutics by 6.0% in the fourth quarter. Aisling Capital LLC now owns 2,990,000 shares of the company’s stock valued at $55,166,000 after buying an additional 170,000 shares during the last quarter.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.